Millions of people come down with influenza (flu) every year, and it affects people differently, but complications of flu include pneumonia, ear infections, sinus infections and worsening of chronic medical conditions such as CHF, asthma or diabetes. Scientists are working to create a more protective vaccine, and we are currently testing one here. By participating in this trial, you will be protected against the flu and help us test a new flu vaccine.

To join, you:

• must be 18 years or older
• must not have received your flu vaccine in the past 6 months

What to expect:

• Length of the trial is approximately 6-12 months
• Up to 4 clinical site visits
• Weekly communication via e-diary
• Compensation for time and travel of about $400

Fill out the volunteer form here if you’d like to be considered for the Flu Vaccine clinical trial.

Respiratory syncytial virus (RSV) is a common respiratory virus that infects the lungs and breathing passages. RSV causes about 177,000 hospitalizations and 14,000 deaths in those over 65 years of age annually in the U.S. It is also the second leading cause of significant respiratory tract illnesses in adults, only behind influenza. The purpose of this clinical trial is to assess the safety of an investigational vaccine aimed at preventing RSV infection in people over 60 years of age or older.

To participate, you must be:

• 60 years of age and older
• In good health
• Primarily responsible for self-care

What to expect:

• Length of the study is approximately 2 years
• 8 visits to the clinical site
• Brief communication via telephone, email, or text messages
• Compensation for time and travel is about $3000

Fill out the volunteer form here if you’d like to qualify for the RSV (Respiratory syncytial virus) Vaccine clinical trial.

Fill out the volunteer form here if you’d like to participate in the FLU and RSV (Respiratory syncytial virus) Vaccine clinical trial.

Enrolling Adults Ages 50-75 Now:

A Clinical Trial Evaluating Investigational mRNA Vaccines for 3 Respiratory Viruses

We are seeking participants for the Trio P101 Trial, evaluating investigational messenger RNA (mRNA) vaccines for 3 respiratory viruses: seasonal influenza (commonly called flu), respiratory syncytial virus (RSV), and SARS-CoV-2 (the virus that causes COVID-19). All 3 can easily spread from person to person, and all 3 can more severely affect people over age 65.1-3

The Potential of mRNA Vaccines

Often, vaccines for viruses are made from a weakened or inactive version of the virus. However, the investigational vaccines in this trial (mRNA-1010, mRNA-1045, mRNA-1273.214, mRNA-1345, and mRNA-1230) are different. They are all mRNA vaccines. These investigational vaccines contain mRNA codes that teach the body’s immune system to recognize and protect itself from the targeted viruses. You cannot become infected with the viruses that cause flu, RSV, or COVID-19 by getting any of these investigational vaccines.

Fewer Injections With the Same Potential Protection

Some of the investigational vaccines in this trial are combination vaccines. Combination vaccines put 2 or more individual vaccines in 1 injection. Combination vaccines can potentially reduce the number of injections you need for protection against common viruses like flu, RSV, and COVID-19. The benefits of combination vaccines include fewer injections, less pain and discomfort, one-time protection, fewer visits to the doctor with less hassle and cost, and less time off from work or family activities. Combination vaccines have existed for several years. For instance, children routinely receive combination vaccines for measles, mumps, and rubella (MMR) and diphtheria, tetanus, and pertussis (DTaP).

Who Can Join?

This clinical trial is looking for adult participants. To join, you must be:

· 50 to 75 years of age

· In good health

· Fully vaccinated for COVID-19 (with or without a booster) for at least 4 months prior to joining the clinical trial

Other criteria may apply in order to be eligible.

What to Expect

The total length of participation in this clinical trial is about 13 months. Potential participants will have a screening visit to check whether they are eligible to participate. If you are eligible and choose to participate, you will have about 6 more in-person visits over the next 13 months.

Fill out the volunteer form here if you’d like to participate in the Trio clinical trial.

This research study is now enrolling to see if it is possible to develop
a cancer screening test based on blood samples.
The study will use blood samples collected from volunteers
who are undergoing routine lung or colon screening.

The purpose of this research study is to collect blood samples and medical information to help in the development of a blood test that can screen for many cancers from a single blood draw. This is an experimental test which is still under development, the goal of this blood test is to help doctors find cancers early, potentially at a time when tumours are still small.
Researchers will look at markers in the blood that show up when cancer is just developing. These findings from the blood, your medical history and results from your routine cancer screening will be used to develop this cancer screening blood test.

Who can take part in this trial?

• Women and men aged between 49-85 years undergoing routine colonoscopy screening.
• Women and men aged between 50-80 years undergoing routine lung cancer screening.
• We are looking for about 75,000 participants from around the world.

Will I be paid to participate in this study?

• To thank you for your time for participating in this research study, you will receive $200 after every blood draw (50 mL of blood) that you provide.
• For each additional blood sample (50 mL of blood) you provide every year for the 4 years this study will last, you will receive an additional $200.
• You may be reimbursed for other reasonable costs associated with blood draw visits (for example, transportation, parking) to travel from your home to the blood draw laboratory or facility.

Fill out the volunteer form here if you’d like to participate in the Lung & Colorectal Cancer Screening Study.

The main focus for the study is to see if the new formulation will reduce shot burden for patients by giving simultaneous protection.

This is a 6 month study with 5 in person visits and 4 safety phone calls. There will be compensation for your time and travel.

In order to participate:

• Must be fully vaccinated for COVID with primary series (at least) and all doses received at least 120 days ago

Fill out the volunteer form here if you’d like to participate in the COVID/FLU Combo Vaccine Study.